Page 8 - குவாங்சோ மருத்துவ பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
health, wellness, napping, sleep, heart disease, heart health, sickness | Y105
iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
health, wellness, napping, sleep, heart disease, heart health, sickness | Majic 95 9
iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma
Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC), and Distal Extrahepatic Tumors (DET).
The most promising way to cure cholangiocarcinoma is surgery, including laparoscopic liver resection and open liver resection. However, the post-surgical outcome is less than satisfactory and there is a poor 5-year survival rate of 16.5-48%. Furthermore, more than two-thirds of the patients are unable to be treated with surgery when diagnosed with cholangiocarcinoma.
E-Mail
Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC) and Distal Extrahepatic Tumors (DET). The most promising way to cure cholangiocarcinoma is surgery, including laparoscopic liver resection and open liver resection. However, the post-surgical outcome is less than satisfactory and there is a poor 5-years survival rate of 16.5-48%. Furthermore, more than two-thirds of the patients are unable to be treated with surgery when diagnosed with cholangiocarcinoma. According to the present meta-analyses, HBV and HCV infections significantly increase the risk of cholangiocarcinoma. For instance, with the high HBV infection rates in Asia and China, the incidence rate of cholangiocarcinoma is approximately 7 per 1 million people in China. Unfortunately, there are no ef
COVID-19 triggers huge rise in donations for research
The COVID-19 outbreak at the beginning of 2020 sparked a huge rise in private philanthropic giving by billionaires and big private company charitable foundations in China with a substantial amount going towards research and development of vaccines, antiviral drugs and other treatments being developed by teams of scientists throughout China but particularly at elite universities and research centres.
A research report on
Pandemic Philanthropy in China by Bridge Consulting’s Beijing Office calculated that some CNY1.8 billion (US$279 million) was contributed to research and development (R&D) in China in the first half of 2020 after a strict lockdown was declared on 23 January 2020 in Wuhan, where the virus is thought to have originated.
vimarsana © 2020. All Rights Reserved.